Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Ability to Calculate the Efficacy of Low-dose Whole Brain RT (WBRT) in Patients With GBM
研究概览
简要总结
In the current proposed trial the role of the low-dose WBRT (0.15 Gy) would be to safely treat the microscopic distant GBM cells outside of the high dose RT region and sensitize the gross tumor, while the focal radiation dose (1.85 Gy) to the gross tumor will bring the total tumor dose of 2 Gy per fraction which is the standard of care.
Radiotherapy (RT) has been integral in the treatment of GBM since the 1970s when Walker et al. showed that post-operative whole brain radiotherapy (WBRT) offered significant improvements in median survival time, and even more so when given with concomitant BCNU chemotherapy. Ensuing dose escalation studies found the optimal dose to be 60 Gy. Patients could not tolerate escalation to higher doses than 60 Gy with WBRT due to unacceptable toxicity. Even with WBRT of 60 Gy, a huge volume of healthy brain tissue was unnecessarily treated with high-dose radiation; recurrences with WBRT remained overwhelmingly local. Hochberg and Pruitt (1980) found that after WBRT only 3% of recurrences were outside 2 cm of the margins of the primary tumor. With the rise of the CT scan in the 1980s and the MRI in the 1990s, along with subsequent improvements in three-dimensional conformal radiation, partial brain RT (PBRT) became practical since tumor margins could be visualized and irradiated more accurately. - Subsequently, WBRT was shown to provide no survival benefit over PBRT at the same dosage; - thus, the latter took over as the standard of care.
详细描述
Radiation Therapy (RT) has been integral in the treatment of GBM since the 1970s. Studies showed that post-operative whole brain radiotherapy (WBRT) offered significant improvements in median survival time, and even more so when given with chemotherapy. Even with WBRT, a huge volume of healthy brain tissue was unnecessarily treated with high-dose radiation; re-growth of tumor with WBRT remained overwhelmingly close to the original tumor site. With the advances in imaging techniques, like CT scans and MRIs, partial brain RT (PBRT) has become a common practice. PBRT is RT given only to the tumor or area of the brain where the cancer was removed. PBRT given with a drug called temozolomide (TMZ) is used as the standard of care treatment for newly diagnosed GBM after surgery.
Current data from our institution suggests that the combination of TMZ with very low-dose WBRT efficiently kills GBM cells. WBRT at conventional higher doses is not given at the same time as TMZ since the severe toxicity risk would be too risky. However, a lower daily WBRT dose, than what is conventionally given to patients, should be tolerable. The randomized trials studying TMZ with low-dose WBRT in patients with brain metastasis did not demonstrate increased serious toxicities associated with TMZ.
PURPOSE OF STUDY Why is the research study being done? The purpose of this study is to determine if low-dose WBRT given in combination with the standard of care TMZ regimen is safe and effective. The role of the low-dose WBRT would be to safely treat the microscopic distant GBM cells outside of the high-dose PBRT region. We will continue to target the tumor with focused PBRT that will bring the total tumor dose to the standard of care dose. This study will find out what effects, good or bad, low-dose WBRT has on you and your cancer.
PROCEDURES How many people will take part in the study? About 47 people will take part in this study. Patient participation in this study is voluntary. The research will be conducted at UMMS.
What will happen if I take part in this research study? Before you begin the study... Patient will need to have the following exams, tests or procedures to find out if you can be in the study. These exams, tests or procedures are part of regular cancer care and may be done even if Patient does not join the study. If he/she has had some of them recently, they may not need to be repeated. This will be up to the study doctor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •3.1.1 Histologically proven diagnosis of glioblastoma or gliosarcoma (WHO grade IV).
- •3.1.2 Infratentorial and multi-focal tumors are eligible. 3.1.3 History and physical with neurological examination, steroid documentation, height, and weight within 14 days of registration.
- •3.1.4 A diagnstic contrast-enhanced MRI of the brain must be performed preoperatively and postoperatively prior to the initiation of radiotherapy. The postoperative scan must be performed within 28 days prior to registration. (contrast enhanced Brain CT is allowed if MRI is contraindicated) 3.1.5 Karnofsky performance status ≥ 70 or ECOG performance status ≤
- •3.1.6 Age ≥
- •3.1.7 CBC with differential obtained within 14 days prior to registration, with adequate bone marrow function defined as follows:
- •Absolute neutrophil count (ANC) ≥ 1,800 cells/mm
- •Platelets ≥ 100,000 cells/mm
- •Hemoglobin ≥ 10.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥10.0 g/dl is acceptable).
- •3.1.8 Adequate renal function within 14 days prior to registration, as defined below:
- •BUN ≤ 30 mg/dl.
- •Creatinine ≤ 1.7 mg/dl. 3.1.9 Adequate hepatic function within 14 days prior to registration, as defined below:
- •Bilirubin ≤ 2.0 mg/dl.
- •ALT/AST ≤ 3 x upper limit of normal (ULN). 3.1.10 Systolic blood pressure ≤ 160 mg Hg or diastolic pressure ≤ 90 mg Hg within 14 days prior to registration.
- •3.1.11 Prothrombin time/international normalized ratio (PT INR) < 1.4 for patients not on warfarin confirmed by testing within 14 days prior to registration. Patients on full-dose anticoagulants (e.g., warfarin or LMW heparin) must meet both of the following criteria:
- •No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices).
- •In-range INR (between 2.5 and 3.5) on a stable dose of warfarin-based oral anticoagulant; or on a stable dose of low molecular weight heparin; or INR between 1.5 and 2 if a Greenfield filter is in place.
- •3.1.12 Patient must provide study specific informed consent prior to study entry.
- •3.1.13 For women of child-bearing potential, negative serum pregnancy test within 14 days prior to registration.
- •3.1.14 Women o f childbearing potential and male participants must practice adequate contraception.
排除标准
- •3.2.1 Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 3 years. For example, carcinoma in situ of the breast, oral cavity, and cervix are all permissible.
- •3.2.2 Metastases beyond the cranial vault. 3.2.3 Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment is not permitted.
- •3.2.4 Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in significant overlap of radiation fields.
- •3.2.5 Severe, active co-morbidity, defined as follows:
- •Unstable angina and/or congestive heart failure within the last 6 months.
- •Transmural myocardial infarction within the last 6 months.
- •New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to registration.
- •History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within 6 months.
- •Serious and inadequately controlled cardiac arrhythmia.
- •Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease.
- •Evidence of bleeding diathesis or coagulopathy.
- •Serious or non-healing wound, ulcer, or bone fracture or history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess, major surgical procedure or significant traumatic injury within 28 days prior to registration, with the exception of the craniotomy for tumor resection or follow-on craniotomies to manage complications of brain tumor management such as hemorrhage or infection.
- •Bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
- •Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.
- •Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol.
- •Acquired immune deficiency syndrome (AIDS) based upon current CDC definition; Note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol are significantly immunosuppressive.
- •Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity.
- •Any other major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy.
- •Cognitive impairment that precludes a patient from acting as his or her own agent to provide informed consent.
- •3.2.6 Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the chemotherapeutic treatment involved in this study is significantly teratogenic.
- •3.2.7 Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant due to study treatment.
- •3.2.8 Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study.
- •3.2.9 Inability to undergo MRI (e.g., due to safety reasons, such as presence of a pacemaker).
研究组 & 干预措施
Low Dose WBRT
Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by either 6 or a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
干预措施: Chemotherapy with Temodar. (Drug)
Low Dose WBRT
Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by either 6 or a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
干预措施: Radiation therapy (Radiation)
结局指标
主要结局
Ability to Calculate the Efficacy of Low-dose Whole Brain RT (WBRT) in Patients With GBM
时间窗: 5 years
Median survival (in months from time of diagnosis to date of death) was calculated and reported below. It is very difficult to draw efficacy outcomes for outcome measure #1 and #2 because of incomplete enrollment.
次要结局
- Radiographic (CT-MRI) Response Assessment and Treatment Failure Patterns of Patients With GBM(5 years)
研究者
Department of Radiation Oncology
Associate Professor
University of Maryland, Baltimore